Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major tendinopathy markets reached a value of US$ 11.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.35% during 2024-2034.
The tendinopathy market has been comprehensively analyzed in IMARC's new report titled "Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tendinopathy refers to a group of conditions characterized by damage, degeneration, or inflammation of tendons, which are thick, fibrous cords that connect muscles to bones. The disease can affect any tendon in the body, but it commonly occurs in the shoulders, elbows, wrists, knees, hips, and ankles. The most common symptoms of this illness include pain, impaired function, tenderness, swelling, stiffness, reduced range of motion, etc. The pain associated with the ailment typically worsens with movement or activity involving the affected tendon. The diagnosis of this disorder relies on a detailed medical history, including information about symptoms, onset, and aggravating factors. A physical examination may be conducted to assess the afflicted region for any signs of inflammation or localized tenderness. The healthcare provider may further perform various diagnostic procedures, such as X-rays, magnetic resonance imaging, ultrasounds, etc., to evaluate real-time images of the tendons. In some cases, blood workups may be required to check for markers of inflammation, like C-reactive protein and erythrocyte sedimentation rate, to confirm a diagnosis among patients.
The increasing cases of biomechanical imbalances on account of improper training techniques during sports, poor posture, structural abnormalities, etc., are primarily driving the tendinopathy market. In addition to this, the rising incidences of various associated risk factors, such as trauma, injury, advancing age, certain systemic diseases, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen, that help to reduce pain and inflammation in individuals suffering from tendinopathy is further bolstering the market growth. Apart from this, the escalating utilization of platelet-rich plasma therapy, which involves injecting a concentrated solution of the patient's own platelets into the affected tendon to promote tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of orthotic devices, such as braces, splints, shoe inserts, etc., since they can provide support and relieve stress, is also augmenting the market growth. Furthermore, the inflating demand for extracorporeal shockwave therapy that aids in stimulating blood flow and enhancing tissue regeneration is expected to drive the tendinopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the tendinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tendinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tendinopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the tendinopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the tendinopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current tendinopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the tendinopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the tendinopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the tendinopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of tendinopathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of tendinopathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of tendinopathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with tendinopathy across the seven major markets?
What is the size of the tendinopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of tendinopathy?
What will be the growth rate of patients across the seven major markets?
Tendinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for tendinopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tendinopathy market?
What are the key regulatory events related to the tendinopathy market?
What is the structure of clinical trial landscape by status related to the tendinopathy market?
What is the structure of clinical trial landscape by phase related to the tendinopathy market?
What is the structure of clinical trial landscape by route of administration related to the tendinopathy market?
The tendinopathy market has been comprehensively analyzed in IMARC's new report titled "Tendinopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tendinopathy refers to a group of conditions characterized by damage, degeneration, or inflammation of tendons, which are thick, fibrous cords that connect muscles to bones. The disease can affect any tendon in the body, but it commonly occurs in the shoulders, elbows, wrists, knees, hips, and ankles. The most common symptoms of this illness include pain, impaired function, tenderness, swelling, stiffness, reduced range of motion, etc. The pain associated with the ailment typically worsens with movement or activity involving the affected tendon. The diagnosis of this disorder relies on a detailed medical history, including information about symptoms, onset, and aggravating factors. A physical examination may be conducted to assess the afflicted region for any signs of inflammation or localized tenderness. The healthcare provider may further perform various diagnostic procedures, such as X-rays, magnetic resonance imaging, ultrasounds, etc., to evaluate real-time images of the tendons. In some cases, blood workups may be required to check for markers of inflammation, like C-reactive protein and erythrocyte sedimentation rate, to confirm a diagnosis among patients.
The increasing cases of biomechanical imbalances on account of improper training techniques during sports, poor posture, structural abnormalities, etc., are primarily driving the tendinopathy market. In addition to this, the rising incidences of various associated risk factors, such as trauma, injury, advancing age, certain systemic diseases, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen, that help to reduce pain and inflammation in individuals suffering from tendinopathy is further bolstering the market growth. Apart from this, the escalating utilization of platelet-rich plasma therapy, which involves injecting a concentrated solution of the patient's own platelets into the affected tendon to promote tissue healing, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of orthotic devices, such as braces, splints, shoe inserts, etc., since they can provide support and relieve stress, is also augmenting the market growth. Furthermore, the inflating demand for extracorporeal shockwave therapy that aids in stimulating blood flow and enhancing tissue regeneration is expected to drive the tendinopathy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the tendinopathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tendinopathy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tendinopathy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the tendinopathy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the tendinopathy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current tendinopathy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the tendinopathy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the tendinopathy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the tendinopathy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of tendinopathy across the seven major markets?
What is the number of prevalent cases (2018-2034) of tendinopathy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of tendinopathy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with tendinopathy across the seven major markets?
What is the size of the tendinopathy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of tendinopathy?
What will be the growth rate of patients across the seven major markets?
Tendinopathy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for tendinopathy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tendinopathy market?
What are the key regulatory events related to the tendinopathy market?
What is the structure of clinical trial landscape by status related to the tendinopathy market?
What is the structure of clinical trial landscape by phase related to the tendinopathy market?
What is the structure of clinical trial landscape by route of administration related to the tendinopathy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TENDINOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 TENDINOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TENDINOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 TENDINOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TENDINOPATHY - UNMET NEEDS
10 TENDINOPATHY - KEY ENDPOINTS OF TREATMENT
11 TENDINOPATHY - MARKETED PRODUCTS
11.1 List of Tendinopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 TENDINOPATHY - PIPELINE DRUGS
12.1 List of Tendinopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TENDINOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TENDINOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TENDINOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tendinopathy - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Tendinopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Tendinopathy - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Tendinopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Tendinopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tendinopathy - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Tendinopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Tendinopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tendinopathy - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Tendinopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Tendinopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tendinopathy - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Tendinopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Tendinopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tendinopathy - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Tendinopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Tendinopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tendinopathy - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Tendinopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Tendinopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tendinopathy - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Tendinopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Tendinopathy - Access and Reimbursement Overview
16 TENDINOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TENDINOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TENDINOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TENDINOPATHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 TENDINOPATHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TENDINOPATHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 TENDINOPATHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TENDINOPATHY - UNMET NEEDS
10 TENDINOPATHY - KEY ENDPOINTS OF TREATMENT
11 TENDINOPATHY - MARKETED PRODUCTS
11.1 List of Tendinopathy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 TENDINOPATHY - PIPELINE DRUGS
12.1 List of Tendinopathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TENDINOPATHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TENDINOPATHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TENDINOPATHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tendinopathy - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Tendinopathy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Tendinopathy - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Tendinopathy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Tendinopathy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tendinopathy - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Tendinopathy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Tendinopathy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tendinopathy - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Tendinopathy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Tendinopathy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tendinopathy - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Tendinopathy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Tendinopathy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tendinopathy - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Tendinopathy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Tendinopathy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tendinopathy - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Tendinopathy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Tendinopathy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tendinopathy - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Tendinopathy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Tendinopathy - Access and Reimbursement Overview
16 TENDINOPATHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TENDINOPATHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TENDINOPATHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
